Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
As a biologic reservoir of <i>Mycobacterium tuberculosis</i> (<i>M. tb</i>), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/10/2398 |
| _version_ | 1797475051514101760 |
|---|---|
| author | Débora Leite Campos Fernanda Manaia Demarqui Mariana Cristina Solcia Paula Carolina de Souza Pedro Ivo da Silva Maia Victor Marcelo Deflon Fernando Rogério Pavan |
| author_facet | Débora Leite Campos Fernanda Manaia Demarqui Mariana Cristina Solcia Paula Carolina de Souza Pedro Ivo da Silva Maia Victor Marcelo Deflon Fernando Rogério Pavan |
| author_sort | Débora Leite Campos |
| collection | DOAJ |
| description | As a biologic reservoir of <i>Mycobacterium tuberculosis</i> (<i>M. tb</i>), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating <i>M. tb</i>, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence. |
| first_indexed | 2024-03-09T20:38:38Z |
| format | Article |
| id | doaj.art-1f032a44ee764587ab3c45d141aed060 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T20:38:38Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-1f032a44ee764587ab3c45d141aed0602023-11-23T23:02:25ZengMDPI AGBiomedicines2227-90592022-09-011010239810.3390/biomedicines10102398Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic MycobacteriaDébora Leite Campos0Fernanda Manaia Demarqui1Mariana Cristina Solcia2Paula Carolina de Souza3Pedro Ivo da Silva Maia4Victor Marcelo Deflon5Fernando Rogério Pavan6Tuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University—UNESP, Araraquara 14800-903, BrazilTuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University—UNESP, Araraquara 14800-903, BrazilTuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University—UNESP, Araraquara 14800-903, BrazilTuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University—UNESP, Araraquara 14800-903, BrazilInstitute of Exact, Natural Sciences and Education, Triangulo Mineiro Federal University—UFTM, Uberaba 38064-200, BrazilInstitute of Exact, Natural Sciences and Education, Triangulo Mineiro Federal University—UFTM, Uberaba 38064-200, BrazilTuberculosis Research Laboratory, School of Pharmaceutical Sciences, São Paulo State University—UNESP, Araraquara 14800-903, BrazilAs a biologic reservoir of <i>Mycobacterium tuberculosis</i> (<i>M. tb</i>), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating <i>M. tb</i>, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.https://www.mdpi.com/2227-9059/10/10/2398latent tuberculosis<i>Mycobacterium tuberculosis</i>treatment |
| spellingShingle | Débora Leite Campos Fernanda Manaia Demarqui Mariana Cristina Solcia Paula Carolina de Souza Pedro Ivo da Silva Maia Victor Marcelo Deflon Fernando Rogério Pavan Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria Biomedicines latent tuberculosis <i>Mycobacterium tuberculosis</i> treatment |
| title | Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
| title_full | Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
| title_fullStr | Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
| title_full_unstemmed | Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
| title_short | Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
| title_sort | latent tuberculosis a promising new compound to treat non replicating and intramacrophagic mycobacteria |
| topic | latent tuberculosis <i>Mycobacterium tuberculosis</i> treatment |
| url | https://www.mdpi.com/2227-9059/10/10/2398 |
| work_keys_str_mv | AT deboraleitecampos latenttuberculosisapromisingnewcompoundtotreatnonreplicatingandintramacrophagicmycobacteria AT fernandamanaiademarqui latenttuberculosisapromisingnewcompoundtotreatnonreplicatingandintramacrophagicmycobacteria AT marianacristinasolcia latenttuberculosisapromisingnewcompoundtotreatnonreplicatingandintramacrophagicmycobacteria AT paulacarolinadesouza latenttuberculosisapromisingnewcompoundtotreatnonreplicatingandintramacrophagicmycobacteria AT pedroivodasilvamaia latenttuberculosisapromisingnewcompoundtotreatnonreplicatingandintramacrophagicmycobacteria AT victormarcelodeflon latenttuberculosisapromisingnewcompoundtotreatnonreplicatingandintramacrophagicmycobacteria AT fernandorogeriopavan latenttuberculosisapromisingnewcompoundtotreatnonreplicatingandintramacrophagicmycobacteria |